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Abstract
Background:  Professional medical organizations recommend individualized patient decision
making about prostate cancer screening. Little is known about primary care physicians' use of pre-
screening discussions to promote informed decision making for prostate cancer screening. The aim
of this study is to explore physicians' use of pre-screening discussions and reasons why physicians
would or would not try to persuade patients to be screened if they initially refuse testing.
Methods: Primary care physicians completed a self-administered survey about prostate cancer
screening practices for informed decision making.
Results: Sixty-six physicians (75.9%) completed the survey, and 63 were used in the analysis.
Thirteen physicians (20.6%) reported not using prescreening discussions, 45 (71.4%) reported the
use of prescreening discussions, and 3 (4.8%) reported neither ordering the PSA test nor discussing
it with patients. Sixty-nine percent of physicians who reported not having discussions indicated they
were more likely to screen African American patients for prostate cancer, compared to 50% of
physicians who reported the use of discussions (Chi-square(1) = 1.62, p = .20). Similarly, 91% of
physicians who reported not having discussions indicated they are more likely to screen patients
with a family history of prostate cancer, compared to 46% of those who reported the use of
discussion (Chi-square(1) = 13.27, p < .001). Beliefs about the scientific evidence and efficacy of
screening, ethical concerns regarding patient autonomy, and concerns about time constraints
differed between physicians who would and would not try to persuade a patient to be tested.
Conclusion: Although guidelines recommend discussing the risks and benefits of prostate cancer
screening, physicians report varying practice styles. Future research needs to consider the nature
of discussions and the degree to which informed decision making is being achieved in clinical
practice.
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Background
Prostate cancer is the most commonly diagnosed non-
skin cancer and the second leading cause of cancer death
among United States men [1]. The 2008 United States Pre-
ventive Services Task Force (USPSTF) evidence report
found insufficient evidence to recommend for or against
routine screening using the prostate-specific antigen
(PSA) test or digital rectal examination (DRE) [2]. Profes-
sional medical organizations recommend informing men
about the potential harms and benefits of prostate cancer
screening, which is commensurate with informed deci-
sion making (IDM) for prostate cancer screening [3-5].
Research about IDM for prostate cancer screening has
largely focused on decision aids and patient involvement
in the decision-making process [6,7]. Little is known
about physicians' practice styles regarding IDM for pros-
tate cancer screening. Purvis Cooper et al. [8] conducted
14 telephone-based focus groups with 75 primary care
physicians (PCPs) in 35 states and identified two predom-
inant practice styles. Non-routine screeners included phy-
sicians who offered PSA testing without recommending
for or against it. Most non-routine screeners reported hav-
ing pre-screening discussions with patients about PSA
testing. Routine screeners included physicians who rec-
ommended PSA testing, and few of them reported having
pre-screening discussions.
Building on the qualitative work of Purvis Cooper et al.
[8], the aim of this study is to explore the use of pre-
screening discussions by PCPs to promote IDM. Second-
arily, we examined the validity of a self-report indicator to
classify physicians as those reporting use of pre-screening
discussions (D = discussing) and those who do not (ND =
non-discussing). We also explored reasons why physi-
cians would or would not try to persuade patients to be
screened if they initially refused PSA testing, and how
their screening practices differ for men in high risk groups
(i.e., African American race, and family history of prostate
cancer).
Methods
Participants and procedures
In February 2004, 87 PCPs from a university-based family
medicine clinic and six community health centers in Hou-
ston, Texas were invited to complete self-administered
surveys. Reminder letters and surveys were sent to nonre-
sponders after three weeks. The Baylor College of Medi-
cine Institutional Review Board approved this study for
use of human subjects in research. PCPs provided
acknowledgement of consent by returning the surveys.
Development and validation of questionnaire survey
A single-item indicator of practice style was developed
based on the pre-screening discussion findings of routine
and non-routine screeners from Purvis Cooper, et al. [8].
The context was screening an age-appropriate man with
no other risk factors for prostate cancer using the PSA test.
The practice style indicator reflected whether clinicians
routinely reported use of pre-screening discussions and,
among clinicians who do (D), their usual decision mak-
ing role (recommend for, recommend against, or let
patient decide). Face validity was established through iter-
ative feedback from 3 PCPs.
Two questions were included to assess screening practices
for high risk men (i.e., African American men and men
with a family history of prostate cancer) compared to
other age-appropriate men without the risk factor.
Response options were "more likely to screen," "less likely
to screen," or "screening practices the same." PCPs also
were asked if they would try to persuade a man to have the
PSA test if he initially refused, and offer reasons why or
why not.
Validity of the practice style indicator was assessed by ask-
ing PCPs how often they order PSA tests for patients who
were screening candidates (response options, "never" to
"always" on a 6-point Likert scale).
Statistical analysis
We calculated the proportion of D and ND respondents.
Validity of the practice style indicator question was exam-
ined using Kruskal-Wallis one-way analysis of variance to
compare physicians' reported frequencies of discussing
screening harms and benefits and how often patients were
screened with PCPs' responses to the practice style indica-
tor. Chi-square tests were used to explore differences in
screening frequency for high risk patients across practice
styles. Descriptive statistics were performed with SPSS
13.0.
Responses to open-ended questions
Responses to open-ended questions about persuading a
man to have the PSA test after he initially refusal were
reviewed by two authors and each response was coded
into themes concerning cancer beliefs. The themes were
grouped by those who would and would not try to per-
suade the patient to have the test.
Results
Sixty-six (75.9%) of the 87 PCPs completed the survey.
Sixty-three (72.4%) were included in the analysis, includ-
ing 35 family physicians and 28 general internists. The
three excluded were 2 urgent care physicians and 1 work-
ing in psychiatry.
Thirteen (20.6%) respondents were classified as ND pro-
viders, 45 (71.4%) were D providers, and 3 (4.8%) pro-
viders reported neither ordering PSA tests nor discussingBMC Family Practice 2009, 10:19 http://www.biomedcentral.com/1471-2296/10/19
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testing with patients. Two physicians marked "other."
Among the D providers, 20 (44.4%) reported they recom-
mend screening and 25 (55.6%) responded they would
let patients decide after discussing harms and benefits (see
Figure 1).
Figure 2 shows the relationship between self-reported
practice style and the frequency of ordering the PSA test.
The reported frequency of ordering PSA tests was highest
among ND PCPs followed by D PCPs who recommend
PSA testing for their patients. D PCPs who let patients
decide about testing reported the lowest frequency of
ordering PSA tests.
Figure 1 shows responses to persuading a man to have a
PSA test after he initially refuses by self-reported practice
style. Of the 13 ND PCPs, 5 (38.5%) indicated they would
persuade the man. Similarly, of the 19 D PCPs who rec-
ommend screening, 7 (36.8%) said they would try to per-
suade the man (one response was missing). Of the 25 D
PCPs who let the patient decide, only 1 (4%) would try to
persuade the man. Themes from the responses to the
open-ended question about why physicians would or
would not try to persuade a patient to be tested if he
refused the PSA test are given in Table 1. Physicians who
would try to persuade a patient to be tested believed in the
efficacy of screening and PSA testing, specifically, and
were concerned that prostate cancer often presents asymp-
tomatically. These PCPs felt screening should be part of
routine care. Physicians who would not try to persuade a
patient to be tested questioned the lack of scientific evi-
dence and efficacy of the PSA test. Some of these PCPs
were concerned about treatment side effects and others
reported there was insufficient time to discuss screening
during clinical encounters. They also noted patient auton-
omy as an important factor.
The majority of PCPs report being more likely to screening
African American men; screening behavior appeared sim-
ilar across practice styles (see Table 2). In contrast, family
history was particular important for PCPs who routinely
discuss prostate cancer screening with their patients. Spe-
cifically, D PCPs seemed more likely to report screening
their patients for prostate cancer if they have a family his-
tory, compared to ND PCPs.
Physicians who would persuade men to have the PSA test after initial refusal Figure 1
Physicians who would persuade men to have the PSA test after initial refusal.
  *2 physicians who marked “other” not shown 
**1 response missing 
Primary Care Physicians*
n=63
Order PSA without 
discussion (ND) 
n=13
Discuss screening with 
patient (D) 
n=45
Do not discuss or order 
PSA  
n=3
D, Recommend
PSA 
n=20
D, Let patient 
decide 
n=25
Would persuade 
undecided men 
n=1
Would persuade 
undecided man 
n=5
Would persuade 
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Discussion
Summary of findings
We found support for two general physician practice styles
related to prostate cancer screening informed decision
making. ND providers who reported not using pre-screen-
ing discussions appear to generally order PSA tests with-
out discussing potential harms and benefits. D providers
who reported using pre-screening discussions also
reported to discuss harms and benefits of testing,
although their decision-making roles varied; specifically,
some let patients decide while others recommend testing.
None of the ND or D physicians reported recommending
against the test. In addition, the practice style question
provided evidence for validity when compared to physi-
cians' reported frequencies of ordering PSA tests.
It is surprising that most physicians in this study reported
discussing screening harms and benefits given the sub-
stantial barriers to promoting IDM in clinical practice [9].
It also is interesting that many of the D providers still rec-
ommend screening to their patients. This finding may
reflect some of the tension between professional guide-
lines and concerns about malpractice resulting from
missed cancer diagnoses [10].
Risk factors appear to play a role in how likely D physi-
cians are to screen patients for prostate cancer. The major-
ity of physicians appear more likely to screen African
American men than other men. Similarly, over 80% of
physicians whose practice pattern for patients with no risk
factors is to discuss prostate cancer screening reported
being more likely to screen patients with family histories
compared with other patients.
When faced with a patient who initially declines PSA test-
ing, some important beliefs help explain physicians'
responses. Beliefs about scientific evidence and efficacy of
screening, ethical concerns regarding patient autonomy,
and pragmatic concerns (e.g., time constraints) seem to be
different between physicians who would and would not
try persuading patients to be tested.
Reported frequency of ordering PSA tests by physician prac- tice style Figure 2
Reported frequency of ordering PSA tests by physi-
cian practice style.
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Table 1: Responses to question about persuading a patient to be screened who refuses the PSA test.±*
Would try to persuade patient to have the PSA test
(n = 13)
Would not try to persuade patient to have the PSA test
(n = 45)
Belief in Early Detection Patient Autonomy
"Because prostate cancer found early is curable." "The patient is the ultimate decision maker."
"How else could you be diagnosed and treated?" "The patient has the final say in his care."
"Patient has the right to refuse after the discussion of the benefit and 
risk of PSA screening."
Asymptomatic Presentation Lack of Scientific Evidence
"Because prostate cancer could be asymptomatic." "No good evidence that screening prevents morbidity & mortality."
"I have a number of asymptomatic patients with increased PSA. 
Therefore, prostate cancer."
Belief in Efficacy of the Test Questionable Efficacy of Test
"Relatively low number false positives." "The test is not specific enough to recommend without reservation 
in low risk people."
"Personally I believe in the benefit." "Test has too many false positives."
Part of Routine Care Time Constraints
"Usually doing other lab work – one more tube if positive then he can 
consider further evaluation if desired."
"Too time intensive."
Concerns about Side Effects
"The complications of biopsy and treatment might outweigh the 
benefit."
± Data from a university-based family medicine clinic and six community health centers in Houston, TX collected in February 2004.
*One response missing.BMC Family Practice 2009, 10:19 http://www.biomedcentral.com/1471-2296/10/19
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Limitations
Limitations of this study include using self-report data
instead of observing discussions between physicians and
patients. Some physicians reported discussing screening
harms and benefits with patients, but the content of such
communications was not investigated. Although only
three PCPs reviewed the practice style question for content
validity, evidence for validity was also seen when com-
pared to a frequency of PSA testing question. The results
of this study are limited a sample of university-based phy-
sicians and may not be generalizable to PCPs in non-aca-
demic settings.
Current Literature about Physicians' IDM Practice Style for Prostate 
Cancer Screening
Existing research has been very limited about physicians'
practice styles regarding IDM for prostate cancer screen-
ing. In comparison to the qualitative work of Purvis
Cooper et al [6], our study also found predominate prac-
tice styles for prostate cancer screening in regards to rou-
tine and non-routine screening, but also practice styles
appear to differ by those who have pre-screening discus-
sions and those who do not. Additionally, many of the
qualitative themes about beliefs about prostate cancer
screening that emerged from Purvis Cooper's study were
also found in the open responses to persuading men
about the PSA test in our study.
Conclusion
Although guidelines recommend discussing potential
harms and benefits of prostate cancer screening, physi-
cians report varying prostate cancer screening practice
styles. Future research needs to consider the nature of
patient-provider discussions and the degree to which IDM
is achieved in clinical practice. Additionally, IDM practice
styles for prostate cancer screening should be explored to
see if styles differ by provider characteristics such as age,
gender, practice setting, and beliefs about prostate cancer
screening.
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